In the latest trading session,, 1.75 million Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) shares changed hands as the company’s beta touched 2.29. With the company’s most recent per share price at $0.89 changed hands at -$0.05 or -4.62% at last look, the market valuation stands at $228.35M. ADAP’s current price is a discount, trading about -130.34% off its 52-week high of $2.05. The share price had its 52-week low at $0.42, which suggests the last value was 52.81% up since then. When we look at Adaptimmune Therapeutics Plc ADR’s average trading volume, we note the 3-month average coming to 1.50 million.
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) trade information
Instantly ADAP was in red as seen in intraday trades today. With action -14.06%, the performance over the past five days has been red. The drop to weekly highs of 1.0800 subtracted -4.62% to the stock’s daily price. The company’s shares are showing year-to-date upside of 12.70%, with the 5-day performance at -14.06% in the red. However, in the 30-day time frame, Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) is -19.48% down.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Adaptimmune Therapeutics Plc ADR (ADAP) estimates and forecasts
Data shows that the Adaptimmune Therapeutics Plc ADR share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 98.61% over the past 6 months, a -4.76% in annual growth rate that is considerably lower than the industry average of 15.60%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 10.30%. The 2024 estimates are for Adaptimmune Therapeutics Plc ADR earnings to decrease by -640.61%, but the outlook for the next 5-year period is at 1.00% per year.
ADAP Dividends
Adaptimmune Therapeutics Plc ADR is expected to release its next quarterly earnings report in July.
